Clinical Colorectal Cancer

Journal Information
ISSN / EISSN : 1533-0028 / 1938-0674
Published by: Elsevier BV (10.1016)
Total articles ≅ 1,383
Current Coverage
SCOPUS
SCIE
MEDICUS
MEDLINE
PUBMED
Archived in
SHERPA/ROMEO
Filter:

Latest articles in this journal

, Y. Nancy You, , , Kanwal Pratap Singh Raghav, Miguel A. Rodriguez-Bigas, Emma Brey Holliday, Grace L. Smith, Bruce D. Minsky, Michael J. Overman, et al.
Published: 8 October 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.012

The publisher has not yet granted permission to display this abstract.
, , Julie Blanc, Olivier Bouché, Eric François, Thierry Conroy, Pascal Artru, Antoine Adenis, Jessica Gobbo, Christophe Borg, et al.
Published: 3 October 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.001

The publisher has not yet granted permission to display this abstract.
Cadham Breanne, Parker Brent, Yin Yaling, Gill Sharlene, Loree Jonathan M, Cheung Winson, Y Davies,
Published: 2 October 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.003

The publisher has not yet granted permission to display this abstract.
Meijiao Zhou, Trevor D. Thompson, Hui-Yi Lin, Vivien W. Chen, Jordan J. Karlitz, Elizabeth T.H. Fontham, Katherine P. Theall, Lu Zhang, , Lori A. Pollack, et al.
Published: 1 October 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.008

Abstract:
Background: The National Comprehensive Cancer Network (NCCN) guidelines have recommended tailored chemotherapy for stage III high-risk (T4 and/or N2) and low-risk (T1-T3 and N1) colon cancer since 2018. Studies have investigated the effect of relative dose intensity (RDI) of FOLFOX on stage III colon cancer survival, however, none has performed a stratified analysis by risk profiles. This study aims to identify the FOLFOX optimal RDI for high-risk and low-risk stage III colon cancer patients. Methods: Data on 407 eligible patients, diagnosed with stage III colon cancer in 2011 who received FOLFOX, were collected by eight population-based cancer registries. Multivariable Cox model and Fine-Gray competing risks model were employed to explore Optimal RDI defined as the lowest RDI administered without significant differences in either overall or cause-specific death. Results: Among the 168 high-risk patients, the optimal RDI cut-off was 70% (HR=1.59 with 95% CI: 0.69-3.66 in overall mortality; HR=1.24 with 95% CI: 0.42-3.64 in cause-specific mortality when RDI<70% vs. RDI≥70%). Among the 239 low-risk patients, none of the evaluated cut-offs were associated with significant differences in risk of death between comparison groups. The lowest assessed RDI was 45%, HR=0.80; 95% CI: 0.24-2.73 for overall mortality and HR=0.53; 95% CI: 0.06-4.95 for cause-specific mortality, when RDI<45% vs. RDI≥45%. Conclusions: There is no significant harm on the risk of death when reducing RDI by <30% for high-risk patients. For the low-risk patients, we found that RDI as low as 45% did not significantly affect the risk of death. MicroAbstract Research on optimal relative dose intensity (RDI) of FOLFOX in stage III colon cancer by risk profiles is scarce. Using cancer registries' data, our study found when the risk of death remained the same, the minimum RDI of FOLFOX was as low as 70% for high-risk stage III colon cancer patients and as low as 45% for low-risk patients.
, Athanasios Pouptsis, Alicja Synowiec, Vasileios Angelis, Liyana Satterthwaite, Sam Khan, Meera Chauhan, Chloe Holden, Sally Young, Christina Karampera, et al.
Published: 26 September 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.009

The publisher has not yet granted permission to display this abstract.
, Brunella Di Stefano, Michele Basso, Carmine Carbone, Floriana Camarda, Marta Ribelli, Annunziato Anghelone, Raffaella Vivolo, Maria Bensi, Maurizio Martini, et al.
Published: 14 September 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.002

, Anke Reinacher-Schick, Jürgen Weitz, Celine Lugnier, Anna-Lena Kraeft, Sarah Wisser, Daniela E. Aust, , Nikolas V Bubnoff, Michael Kramer, et al.
Published: 14 September 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.005

The publisher has not yet granted permission to display this abstract.
Jeroen F. Schouten, Jeroen Willems, Stefan J.W.J. Sanders, Geert-Jan Creemers,
Published: 14 September 2021
Clinical Colorectal Cancer; https://doi.org/10.1016/j.clcc.2021.09.004

The publisher has not yet granted permission to display this abstract.
Back to Top Top